Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UanQiHuoLi Tang (YQ1) is a traditional Chinese herbal medicine formulation developed by Taipei Veterans General Hospital for the treatment of advanced non-small cell lung cancer (NSCLC), specifically in patients with EGFR/ALK wild-type (EGFR-negative) tumors. Administered orally, it is typically used as an adjunctive therapy alongside cisplatin-based chemotherapy. The formulation is believed to exert antineoplastic and immunostimulating effects by modulating the immune response, inducing apoptosis in tumor cells, and inhibiting cancer cell proliferation. It may also target cancer stem cells and influence the gut microbiota to improve clinical outcomes. Taipei Veterans General Hospital has sponsored Phase 2 clinical trials to evaluate its efficacy and safety in patients with advanced lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UanQiHuoLi Tang.